X

Drug Profile

Glanzmann thrombasthenia gene therapy

Alternative Names: Integrin alpha-IIb-beta3 gene therapy

Latest Information Update: 23 Aug 2002

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nexell Therapeutics [CEASED]
Class Gene therapies
Mechanism of Action

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Thrombasthenia

Most Recent Events

20 Aug 2002 Discontinued - Preclinical for Thrombasthenia in USA (unspecified route)
15 May 2002 Nexell Therapeutics has announced the winding down of company operations
07 Aug 2000 Preclinical development for Thrombasthenia in USA (Unknown route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com